Qilian International Holding Group Limited (QLI), founded in 2019 and headquartered in Jiuquan, People's Republic of China, focuses on the research, development, and production of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMDs), and a variety of other products. The company's diverse offerings include licorice-derived products such as Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, supplied to pharmaceutical companies for manufacturing traditional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient for producing compound licorice oral solutions. QLI also produces Qilian Shan oxytetracycline tablets, used to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and humans, alongside Qilian Shan oxytetracycline APIs for other pharmaceutical manufacturers.